.png)
（ 母液浓度为 40 mg/mL ）, 如您需要配置的浓度超过该产品的溶解度，请先与我们客服联系。| 中文名称: | PF-AKT400 一键复制产品信息 | ||||
|---|---|---|---|---|---|
| 英文名称: | PF-AKT400 | ||||
| 别名: | (S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-d]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺;(S)-N-[[3-氨基-1-(5-乙基-7H-吡咯并[2,3-D]嘧啶-4-基)吡咯烷-3-基]甲基]-2,4-二氟苯甲酰胺 AKT protein kinase inhibitor;N-{[(3s)-3-Amino-1-(5-Ethyl-7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)pyrrolidin-3-Yl]methyl}-2,4-Difluorobenzamide | ||||
| CAS No: | 1004990-28-6 | 分子式: | C20H22F2N6O | 分子量: | 400.43 |
| CAS No: | 1004990-28-6 | ||||
| 分子式: | C20H22F2N6O | ||||
| 分子量: | 400.43 | ||||
包装规格：
5mg 10mg 50mg 100mg in glass bottle
溶解性：
溶于DMSO(≥100mg/mL）
产品描述：
基本信息
|
产品编号： |
P11734 |
||||
|
产品名称： |
PF-AKT400 |
||||
|
CAS: |
1004990-28-6 |
储存条件 |
粉末 |
-20℃ |
四年 |
|
|
|
||||
|
分子式： |
溶于液体 |
-80℃ |
6个月 |
||
|
分子量： |
400.43 |
-20℃ |
1个月 |
||
|
化学名： |
AKT protein kinase inhibitor;N-{[(3s)-3-Amino-1-(5-Ethyl-7h-Pyrrolo[2,3-D]pyrimidin-4-Yl)pyrrolidin-3-Yl]methyl}-2,4-Difluorobenzamide |
||||
|
Solubility (25°C)： |
|||||
|
体外:
|
DMSO |
|
|||
|
Ethanol |
|
||||
|
Water |
|
||||
|
体内(现配现用): |
|
||||
|
＜1mg/ml表示微溶或不溶。 |
|||||
|
普西唐提供的所有化合物浓度为内部测试所得，实际溶液度可能与公布值有所偏差，属于正常的批间细微差异现象。 |
|||||
|
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；⼀旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 |
|||||
制备储备液
|
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
|
1mM |
2.4973mL |
12.4866mL |
24.9732mL |
|
5mM |
0.4995mL |
2.4973mL |
4.9946mL |
|
10mM |
0.2497mL |
1.2487mL |
2.4973mL |
生物活性
|
产品描述 |
一种有效的,ATP竞争性的选择性Akt抑制剂，对PKBα(IC50=0.5nM)的选择性比PKA (IC50=450nM)高900倍。 |
|
|
靶点 |
PKBα 0.5nM (IC50) |
PKA 450nM (IC50) |
|
体外研究 |
PF-AKT400 (Compound 42) provides significantly enhanced selectivity for Akt relative to earlier leads such as spiroindoline 2.Free IC50 and EC50 values are estimated for phospho-S6 reduction (110nM) and Akt hyperphosphorylation (216nM),respectively.These values corresponded well to the cellular IC50 for PF-AKT400 in U87 cells measuring p-GSK-3α(310nM). |
|
|
体内研究 |
PF-AKT400 is subsequently evaluated for modulation of Akt in tumors and in multiple in vivo mouse models of antitumor efficacy.It is active in a PC3 prostate carcinoma xenograft experiment,with 75% TGI observed at 100mg/kg b.i.d.dosing for 10 days.In a colorectal carcinoma (Colo205) xenograft study,PF-AKT400 produces 60% TGI at 150mg/kg b.i.d.after 10 days.Most intriguingly,in combination with Rapamycin (10mg/kg,ip),75mg/kg b.i.d.(10 days) of PF-AKT400 results in 98% TGI in an additional PC3 prostate carcinoma xenograft study compared to 56% TGI and 66% TGI with PF-AKT400 and Rapamycin as single agents.To define the in vivo potency of PF-AKT400 (Compound 42) in the PC3 xenograft model, oral administration of 25,75,and 100mg/kg PF-AKT400 is performed with blood and tumor sampling over time.Immunoblot analysis of detergentsoluble extracts derived from PC3 tumors shows a significant reduction of S6 phosphorylation,and hyperphosphorylation of Akt upon treatment at doses that produced significant tumor growth inhibition.Plasma drug concentrations peak rapidly after oral administration of doses between 25-100mg/kg (Tmax=0.5h).Peak PD responses of phospho-S6 and phospho-Akt are observed at approximately 2-4h and 1h post-administration of PF-AKT400,respectively.The time-course of PD marker response is well described by a PK/PD model at doses that ranged from no efficacy (25mg/kg) to maximal efficacy (100mg/kg). |
|
推荐实验方法(仅供参考)
|
激酶实验： |
|
A fluorescence polarization IMAP type assay is used. An amount of 15μL of diluted PF-AKT400 (Compound 42) in DMSO is mixed with 60μL of reaction buffer (10mM Tris-HCl,pH 7.5,10mM MgCl2,0.1mM EGTA,0.01% Triton-X100,1mM DTT).Then 5μL of the compound/buffer mixture,10μL of a solution containing 4μM ATP and 40nM fluorescent-labeled Crosstide (Tamara-labeled GRPRTSSFAEG peptide),and 5μL of Akt1 protein (lacking the pleckstrin homology (PH) domain,containing an Asp at position 473,and prephosphorylated at Thr 308) in reaction buffer are combined.After a 90 min incubation,IMAP beads are added and plates are read (lamp filter,544nm;emission filter,615nm).The same procedure can be applied to full length Akt1 to provide similar results. All IC50 values are the geometric mean of at least n=2 determinations. |
|
动物实验: |
|
|
Mice Studies to describe the PK/PD relationship for PF-AKT400 are performed in male SCID/Beige mice bearing subcutaneous PC3 prostate carcinoma xenografts.Once tumors reach about ~300mm3 in size,PF-AKT400 is formulated in 0.5% methylcellulose vehicle and administered orally to 3 mice per dose group.Plasma and tumors are harvested over time,tumor lysates prepared,and the levels of phospho S6 reduction and phospho Akt induction are evaluated by immunoblot. |
|
保存条件：
-20℃
UN码：
HazardClass：
危害声明：
安全说明：
搜索质检报告(COA)
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为：
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液，使用的计算公式为：
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为：C1V1 = C2V2 ( 输入 输出 )
(2).jpg)
体内配方的制备方法: 取 50μLDMSO 母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清
方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
母液，添加 300 μLPEG300 混匀澄清，再加 50μLTween80, 混匀澄清，再加 600μLSaline/PBS/ddH2O 混匀澄清方案所需的各种助溶剂如： DMSO ， PEG300 / PEG400 ， Tween 80 ， SBE-β-CD ， 玉米油 等， 均可点击跳转或在网站搜索购买。
以上为“动物实验计算换算器”的使用方法举例，并不是具体某个试剂的配制，请根据您的实验动物和给药方式选择适当的溶解方案。
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL Saline/PBS/ddH2O，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
剂量转换
对于不同动物的给药剂量换算，您也可以参考 更多
